72 related articles for article (PubMed ID: 29773932)
1. Effectiveness and Tolerability of Therapy With Once-Weekly Exenatide Versus Basal Insulin Among Injectable-Naive Patients With Type 2 Diabetes in a Real-World Setting in the United States.
Loughlin AM; Qiao Q; Nunes AP; Ezzy SM; Yochum L; Clifford CR; Gately RV; Dore DD; Seeger JD
Diabetes Spectr; 2018 May; 31(2):129-137. PubMed ID: 29773932
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and tolerability of therapy with exenatide once weekly vs basal insulin among injectable-drug-naïve elderly or renal impaired patients with type 2 diabetes in the United States.
Loughlin AM; Qiao Q; Nunes AP; Öhman P; Ezzy S; Yochum L; Clifford CR; Gately R; Dore DD; Seeger JD
Diabetes Obes Metab; 2018 Apr; 20(4):898-909. PubMed ID: 29193561
[TBL] [Abstract][Full Text] [Related]
3. Tolerability and Effectiveness of Exenatide Once Weekly Relative to Basal Insulin Among Type 2 Diabetes Patients of Different Races in Routine Care.
Nunes AP; Loughlin AM; Qiao Q; Ezzy SM; Yochum L; Clifford CR; Gately RV; Dore DD; Seeger JD
Diabetes Ther; 2017 Dec; 8(6):1349-1364. PubMed ID: 28983857
[TBL] [Abstract][Full Text] [Related]
4. Glucose Control and Weight Change Associated with Treatment with Exenatide Compared with Basal Insulin: A Retrospective Study.
Morgan CL; Qiao Q; Grandy S; Johnsson K; Jenkins-Jones S; Holden S; Currie CJ
Diabetes Ther; 2018 Feb; 9(1):269-283. PubMed ID: 29318537
[TBL] [Abstract][Full Text] [Related]
5. Healthcare resource utilization and related financial costs associated with glucose lowering with either exenatide or basal insulin: A retrospective cohort study.
Holden SE; Morgan CL; Qiao Q; Jenkins-Jones S; Berni ER; Currie CJ
Diabetes Obes Metab; 2017 Aug; 19(8):1097-1105. PubMed ID: 28218819
[TBL] [Abstract][Full Text] [Related]
6. Exenatide once weekly versus daily basal insulin as add-on treatment to metformin with or without a sulfonylurea: a retrospective pooled analysis in patients with poor glycemic control.
Grimm M; Li Y; Brunell SC; Blase E
Postgrad Med; 2013 Sep; 125(5):101-8. PubMed ID: 24113668
[TBL] [Abstract][Full Text] [Related]
7. Comparison of extended release GLP-1 receptor agonist therapy versus sitagliptin in the management of type 2 diabetes.
Stolar MW; Grimm M; Chen S
Diabetes Metab Syndr Obes; 2013; 6():435-44. PubMed ID: 24285927
[TBL] [Abstract][Full Text] [Related]
8. All-cause and diabetes-related healthcare costs among US adults with type 2 diabetes initiating exenatide once weekly or insulin glargine.
Wittbrodt E; Kong AM; Moore-Schiltz L; Juneau P
Diabetes Obes Metab; 2018 Mar; 20(3):672-680. PubMed ID: 29083520
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of exenatide once-weekly versus dulaglutide, liraglutide, and lixisenatide for the treatment of type 2 diabetes mellitus: an analysis from the UK NHS perspective.
Chuang LH; Verheggen BG; Charokopou M; Gibson D; Grandy S; Kartman B
J Med Econ; 2016 Dec; 19(12):1127-1134. PubMed ID: 27310712
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of exenatide once-weekly vs exenatide twice-daily in Asian patients with type 2 diabetes mellitus.
Ji L; Onishi Y; Ahn CW; Agarwal P; Chou CW; Haber H; Guerrettaz K; Boardman MK
J Diabetes Investig; 2013 Jan; 4(1):53-61. PubMed ID: 24843631
[TBL] [Abstract][Full Text] [Related]
11. Dynamic risk factors associated with non-severe hypoglycemia in patients treated with insulin glargine or exenatide once weekly.
Paul SK; Maggs D; Klein K; Best JH
J Diabetes; 2015 Jan; 7(1):60-7. PubMed ID: 25168883
[TBL] [Abstract][Full Text] [Related]
12. Safety and Efficacy of Exenatide Once Weekly in Participants with Type 2 Diabetes and Stage 2/3 Chronic Kidney Disease.
Guja C; Frías JP; Suchower L; Hardy E; Marr G; Sjöström CD; Jabbour SA
Diabetes Ther; 2020 Jul; 11(7):1467-1480. PubMed ID: 32306296
[TBL] [Abstract][Full Text] [Related]
13. Exenatide once weekly for the treatment of type 2 diabetes mellitus: clinical results in subgroups of patients using different concomitant medications.
Pencek R; Brunell SC; Li Y; Hoogwerf BJ; Malone J
Postgrad Med; 2012 Jul; 124(4):33-40. PubMed ID: 22913892
[TBL] [Abstract][Full Text] [Related]
14. Cost-utility of exenatide once weekly compared with insulin glargine in patients with type 2 diabetes in the UK.
Beaudet A; Palmer JL; Timlin L; Wilson B; Bruhn D; Boye KS; Lloyd A
J Med Econ; 2011; 14(3):357-66. PubMed ID: 21563878
[TBL] [Abstract][Full Text] [Related]
15. Real-world clinical responses in patients with type 2 diabetes mellitus adding exenatide BID (EBID) or mealtime insulin to basal insulin: a retrospective study using electronic medical record data.
Lang K; Nguyen H; Huang H; Bauer E; Levin P
Curr Med Res Opin; 2018 Jun; 34(6):1045-1051. PubMed ID: 29394878
[TBL] [Abstract][Full Text] [Related]
16. Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without Heart Failure and Heart Failure-Related Outcomes: Insights From the EXSCEL Trial.
Fudim M; White J; Pagidipati NJ; Lokhnygina Y; Wainstein J; Murin J; Iqbal N; Öhman P; Lopes RD; Reicher B; Holman RR; Hernandez AF; Mentz RJ
Circulation; 2019 Nov; 140(20):1613-1622. PubMed ID: 31542942
[TBL] [Abstract][Full Text] [Related]
17. Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial.
Clegg LE; Penland RC; Bachina S; Boulton DW; Thuresson M; Heerspink HJL; Gustavson S; Sjöström CD; Ruggles JA; Hernandez AF; Buse JB; Mentz RJ; Holman RR
Cardiovasc Diabetol; 2019 Oct; 18(1):138. PubMed ID: 31640705
[TBL] [Abstract][Full Text] [Related]
18. Real-world glycemic outcomes in patients with type 2 diabetes initiating exenatide once weekly and liraglutide once daily: a retrospective cohort study.
Saunders WB; Nguyen H; Kalsekar I
Diabetes Metab Syndr Obes; 2016; 9():217-23. PubMed ID: 27486339
[TBL] [Abstract][Full Text] [Related]
19. The cost-effectiveness of exenatide once weekly compared with exenatide twice daily and insulin glargine for the treatment of patients with type two diabetes and body mass index ≥30 kg/m(2) in Spain.
Fonseca T; Clegg J; Caputo G; Norrbacka K; Dilla T; Alvarez M
J Med Econ; 2013 Jul; 16(7):926-38. PubMed ID: 23659201
[TBL] [Abstract][Full Text] [Related]
20. Comparison of trajectories of self-monitored glucose levels by hypoglycemia status over 52 weeks of treatment with insulin glargine or exenatide once weekly.
Paul SK; Agbeve J; Maggs D; Best JH
J Diabetes; 2016 Jan; 8(1):148-57. PubMed ID: 25586464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
